Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Macrophage apoptosis in advanced atherosclerosis.

Annals of the New York Academy of Sciences·2009

Same author

Calcium/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways.

The Journal of clinical investigation·2009

Same author

Cripto-1 overexpression is involved in the tumorigenesis of nasopharyngeal carcinoma.

BMC cancer·2009

Same author

Range of motion and orientation of the lumbar facet joints in vivo.

Spine·2009

Same author

[Silencing of COX-2 in nasopharyngeal carcinoma cells with a shRNAmir lentivirus vector].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University·2009

Same author

The risk of melamine-induced nephrolithiasis in young children starts at a lower intake level than recommended by the WHO.

Pediatric nephrology (Berlin, Germany)·2009

Search research articles

Related Experiment Video

Updated: Jul 7, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Dendritic cell-based immunotherapy for malignant glioma.

Jin-Hai Gu¹, Gang Li

¹Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan 250012, China.

Neuroscience Bulletin

|February 15, 2008

Summary

Dendritic cell (DC) vaccination shows promise for malignant glioma immunotherapy by overcoming the central nervous system's (CNS) immunosuppressive environment. Further advancements in DC preparation and antigen selection aim to enhance clinical benefits for brain cancer patients.

More Related Videos

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Experiment Videos

Last Updated: Jul 7, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Area of Science:

Neuro-oncology
Immunology
Biotechnology

Background:

Malignant glioma immunotherapy is challenging due to the blood-brain barrier, lack of CNS lymphatic tissue, and an immunosuppressive microenvironment.
Overcoming the compromised immune status in glioma patients is crucial for effective immunotherapeutic approaches.

Purpose of the Study:

To highlight dendritic cell (DC)-based immunotherapy as a promising strategy for malignant glioma.
To discuss the potential of DC vaccination to overcome the immunosuppressive state in the CNS.

Main Methods:

Review of current challenges and advancements in DC-based immunotherapy for malignant glioma.
Focus on the optimization of DC preparation, antigen selection, and administration strategies.

Main Results:

DC vaccination offers a potential method to partially overcome the immunosuppressive environment in malignant glioma.
Ongoing advancements in molecular biology and gene engineering are refining DC immunotherapy techniques.

Conclusions:

DC vaccination is a leading immunotherapy approach for malignant glioma, with ongoing research improving its efficacy.
Further clinical trials and technological advancements are expected to increase the clinical benefits of DC vaccination for brain tumors.